The Effect of Adverse Drug Reactions (ADRs) of Anti-psychotics on the Quality of Life of Outpatients with Schizophrenia at Soerojo Hospital, Magelang, Indonesia
DOI:
https://doi.org/10.31603/evxwjt61Kata Kunci:
Adverse drug reactions (ADRs), Anti-psychotics, Quality of life, WHOQOL-BREF, SchizophreniaAbstrak
Mental disorders are serious conditions of the brain that manifest as abnormalities that affect a person's behavior and character. Schizophrenia is one type of mental disorder that is widely experienced by the community. The primary therapy for schizophrenia is anti-psychotics with routine and long-term medication, which leads to Adverse Drug Reactions (ADRs). ADRs that appear have the potential to affect the quality of life of schizophrenia patients. The purpose of this study was to determine the effect of ADRs on the quality of life of schizophrenia patients at Soerojo Hospital Magelang. The study used a cross-sectional design. The population in this study was patients diagnosed with schizophrenia with consecutive sampling. The instruments used were the Naranjo and WHOQOL-BREF questionnaires to assess the quality of life of schizophrenia patients. Data analysis was conducted univariately using frequency distributions and bivariately using the nonparametric Mann-Whitney test. During the study, 109 patients met the inclusion and exclusion criteria. The majority of patients were male (59.63%), aged 41-60 years (55.96%), had been on treatment for 4-10 years (75.23%), had a high school education (39.45%), were taking a combination of clozapine and risperidone (29.36%), ADRs (71.55%), and had a moderate quality of life (55.05%). The most common ADRs experienced by patients using first-generation anti-psychotics were tremor, nausea, dizziness, and excessive salivation, each occurring at 9.09%. Meanwhile, the most common ADR for second-generation anti-psychotics was drowsiness (34.03%). ADRs were not significantly related to the quality of life of schizophrenia patients (p = 0.941
Referensi
Aloba, O., Fatoye, O., Mapayi, B., & Akinsulore, S. (2013). A review of quality of life studies in nigerian patients with psychiatric disorders. African Journal of Psychiatry (South Africa), 16(5), 333–337. https://doi.org/10.4314/ajpsy.v16i5.44
Aprilia, S., Furqon, M. T., & Fauzi, M. A. (2018). Klasifikasi Penyakit Skizofrenia dan Episode Depresi pada Gangguan Kejiwaan dengan Menggunakan Metode Support Vector Machine (SVM). Jurnal Pengembangan Teknologi Informasi Dan Ilmu Komputer, 2(11), 5611–5618.
Ayunita, S. R., & Nuralita, N. S. (2018). Hubungan Simtom Depresi terhadap Perilaku Merokok pada Pasien Skizofrenia Relation of Depression Symptom to Smoking Behavior in Schizophrenic Patients in Mental Hospital Prof . Dr . H . M . Ildrem Medan. Anatomica Medical Journal Fakultas Kedokteran, 1(2).
Caykoylu, A., Karslioglu, E. H., Bal, N. B., & Kocberber, C. (2022). When and why aripiprazole causes extrapyramidal side effects: Three cases and mini review. Psychiatry Research Case Reports, 1(2), 100066. https://doi.org/10.1016/j.psycr.2022.100066
Chawla, S., & Kumar, S. (2017). Original Article Adverse Drug Reactions and their Impact on Quality of Life in Patients on Anti-psychotic Therapy at a Tertiary Care Center in Delhi. 293–298. https://doi.org/10.4103/0253-7176.207332
Citrome, L. (2017). Activating and sedating adverse effects of second-generation anti-psychotics in the treatment of schizophrenia and major depressive disorder: Absolute risk increase and number needed to harm. Journal of Clinical Psychopharmacology, 37(2), 138–147. https://doi.org/10.1097/JCP.0000000000000665
Efendi, S., & Nugraha, A. (2019). Intervensi Pemulihan Psikososial unutk Pasien dengan Gangguan Jiwa atau Schizophrenia : Studi Literatur. Konferensi Nasional (Konas) XVI Keperawatan Kesehatan Jiwa, 94–105.
Essali, A., Turkmani, K., Aboudamaah, S., AbouDamaah, A., Diaa Aldeen, M. R., Marwa, M. E., & AlMounayer, N. (2019). Haloperidol discontinuation for people with schizophrenia. The Cochrane Database of Systematic Reviews, 4(4), CD011408. https://doi.org/10.1002/14651858.CD011408.pub2
Farida, R., Karuniawati, H., Wikantyasning, E., Sukmawati, A., Cholisoh, Z., Nurwaini, S., & Kumala, M. T. (2025). Psikoedukasi Kesehatan Mental Berbasis Komunitas pada Warga Negara Indonesia di Seoul Korea Selatan. Abdimas Galuh, 2(2).
Fujimaki, K., Takahashi, T., & Morinobu, S. (2012). Association of Typical versus Atypical Anti-psychotics with Symptoms and Quality of Life in Schizophrenia. 7(5). https://doi.org/10.1371/journal.pone.0037087
Hafifah, A., Puspitasari, I. M., Sinuraya, R. K., Farmasi, F., & Padjadjaran, U. (2012). Farmakoterapi dan Rehabilitasi Psikososial pada Skizofrenia. Farmaka, 16(2), 210–232.
Handayani, D. S., Cahaya, N., Srikartika, V. M., & Selatan, K. (2017). Pengaruh Pemberian Kombinasi Antipsikotik Terhadap Efek Samping Sindrom Ekstrapiramidal Pada Pasien Skizofrenia Di Rumah Sakit Jiwa Sambang Lihum. 15, 86–95.
Indriani, A., Ardiningrum, W., & Febriyanti, Y. (2019). Studi Penggunaan Kombinasi Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Yogyakarta. 4(Suppl 1), 201–211.
Iqbal, E., Govind, R., Romero, A., Dzahini, O., Broadbent, M., Stewart, R., Smith, T., Kim, C. H., Werbeloff, N., MacCabe, J. H., Dobson, R. J. B., & Ibrahim, Z. M. (2020). The side effect profile of Clozapine in real world data of three large mental health hospitals. PLoS ONE, 15(12 December), 1–21. https://doi.org/10.1371/journal.pone.0243437
Ishiwata, T., & Seyama, K. (2014). The Relationship Between Smoking and Skizofrenia. Jurnal Agromed Unila, 1. https://pdfs.semanticscholar.org/efec/a50d97041b8ab995924f41435c8d38b60683.pdf
Karuniawati, H., Sari, N., Hossain, M. S., Ismail, W. I., Haq, A. H. B., Yulianti, T., Taufik, T., & Sudarsono, G. R. (2022). Assessment of Mental Health and Quality of Life Status of Undergraduate Students in Indonesia during COVID-19 Outbreak: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 19(19). https://doi.org/10.3390/ijerph191912011
Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, M. F., Young, A. S., Degenhardt, A., & Hong, S. H. (2020). The American psychiatric association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 177(9), 868–872. https://doi.org/10.1176/appi.ajp.2020.177901
Kemkes RI. (2019). Rencana Aksi Program Pencegahan dan Pengendalian Penyakit 2015-2019. Kementerian Kesehatan RI, 2019(2). http://www.jikm.unsri.ac.id/index.php/jikm
Lähteenvuo, M., & Tiihonen, J. (2021). Anti-psychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. Drugs, 81(11), 1273–1284. https://doi.org/10.1007/s40265-021-01556-4
Lestari, W. A., Mitra, & Nurlisis. (2024). Factors Associated with The Occurrence of Schizophrenia in Outpatients at Hospitals Handsome Riau Province in 2022 Faktor-Faktor yang Berhubungan Dengan Kejadian Skizofrenia Pada Pasien Rawat Jalan Di Rumah Sakit Jiwa Tampan Provinsi Riau Tahun 2022. Jurnal Kesehatan Masyarakat Mulawarman, 6(2), 50–58. https://e-journals.unmul.ac.id/index.php/MJPH/article/view/15305/pdf
Meyta Sari, C., & Suprapti, B. (2024). Adverse Drug Reactions Reporting Profile in Tertiary Referral Hospital: A Retrospective Pharmacovigilance Study in Indonesia. Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia, 11(2), 174–183. Https://Doi.Org/10.20473/Jfiki.V11i22024.174-183.
Muliyani, M. M. (2019). Karakteristik Pasien Skizofrenia Rawat Jalan Di Poli Jiwa Rsud. Dr. H. Moch. Ansari Saleh Banjarmasin. Jurnal Kajian Ilmiah Kesehatan Dan Teknologi, 1(2), 21–25. https://doi.org/10.52674/jkikt.v1i2.17
Nucifora, F. C., Mihaljevic, M., Lee, B. J., & Sawa, A. (2017). Clozapine as a Model for Anti-psychotic Development. Neurotherapeutics, 14(3), 750–761. https://doi.org/10.1007/s13311-017-0552-9
Oktrinalida, A. M., Shahab, A., & Suryani, P. R. (2019). Kualitas Hidup Pasien Skizofrenia di Poliklinik Rawat Jalan Rumah Sakit Ernaldi Bahar Palembang. Sriwijaya Journal of Medicine, 2(2), 68–75.
Oommen, S., Elango P, E., Alwar MC, A., & Solomon, S. (2019). Adverse Drug Reactions Affiliated with Atypical Anti-psychotics in Patients with Schizophrenia. Journal of Young Pharmacists, 11(3), 315–319. https://doi.org/10.5530/jyp.2019.11.64
Purwandityo, A., Febrianti, Y., Sari, C. P., Ningrum, V. D. A., & Sugiyarto, O. P. (2018). The Influence of Anti-psychotic to Decrease the Score of The Positive and Negative Syndrome Scale-Excited Component. Indonesian Journal of Clinical Pharmacy, 7(1), 19–29. https://doi.org/10.15416/ijcp.2018.7.1.19
Puspasari, H. W., Sitorus, N., & Agustiya, R. I. (2023). Innovation for Empowering People with Schizophrenia in Empowered Homes Denpasar City. 8(1), 39–57.
Ramsi, R. K., & Zulaikha, A. (2022). Patofisiologi dan Tatalaksana Sindrom Ekstrapiramidal. AVERROUS: Jurnal Kedokteran Dan Kesehatan Malikussaleh, 8(2), 64–76. https://doi.org/10.29103/averrous.v8i2.8770
Refnandes, R., & Almaya, Z. (2022). Faktor-faktor yang mempengaruhi kepatuhan minum obat pada pasien skizofrenia. Jurnal Riset Rumpun Ilmu Kedokteran, 1(2), 01–11. https://doi.org/10.55606/jurrike.v1i2.367
Rodolico, A., Siafis, S., Bighelli, I., Samara, M. T., Hansen, W.-P., Salomone, S., Aguglia, E., Cutrufelli, P., Bauer, I., Baeckers, L., & Leucht, S. (2022). Anti-psychotic dose reduction compared to dose continuation for people with schizophrenia. The Cochrane Database of Systematic Reviews, 11(11), CD014384. https://doi.org/10.1002/14651858.CD014384.pub2
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010). Head-to-head comparisons of metabolic side effects of second generation anti-psychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 123(2–3), 225–233. https://doi.org/10.1016/j.schres.2010.07.012
Saharuddin, Ikawati, A. Z., & Kristanto, S. C. (2021). Comparison Of The Effectiveness Of Anti-psychotic Therapy Regimens For Schizophrenia Patients In RSJ DR. Ernaldi Bahar Palembang.
Saputri, R. P., Endang, E., & Kartika, M. (2018). Analisis Rasionalitas Penggunaan Antipsikotik Pada Pasien Skizofrenia Di Instalasi Rawat Inap RSJD Atma Husada Mahakam Samarinda Tahun 2016 Rationality of Antipsicotic Use in Hospitalized Skizofrenia Patients in RSJD Atma Husada Mahakam Samarinda 2016. 15(1), 19–28.
Turk, T., Zuhri Yafi, R., Namous, L., Alkhaledi, A., Salahia, S., Haider, A. Y., & Essali, A. (2017). Fluphenazine (dose) for people with schizophrenia. Cochrane Database of Systematic Reviews, 2017(10). https://doi.org/10.1002/14651858.CD012848
Yulianty, M. D., Cahaya, N., & Srikartika, V. M. (2017). Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. Jurnal Sains Farmasi & Klinis, 3(2), 153. https://doi.org/10.29208/jsfk.2017.3.2.108
